Letters Section Editor: Jody W. Zylke, MD, Senior Editor.
Author Affiliations: Department of Thoracic Surgery, Sapienza University of Rome, Rome, Italy (email@example.com).
To the Editor: Dr Kratz and colleagues1 suggested that the use of a new molecular assay could affect prognosis and therapeutic strategy in patients with small, node-negative non–small cell lung cancer (NSCLC). This assay has been previously validated by the same authors in an international population with nonsquamous NSCLC.2 Some points about the results need to be considered.
Anile M, Venuta F. Prognostic Assay in Small, Node-Negative Non–Small Cell Lung Cancer. JAMA. 2013;309(8):769-770. doi:10.1001/jama.2012.211724